New drug aims to protect hearts after bypass surgery

NCT ID NCT07192211

Recruiting now Disease control Sponsor: Rohto Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called ADR-002K in 50 people with heart failure caused by blocked heart arteries who are scheduled for bypass surgery. The goal is to see if the drug can prevent heart-related events and improve heart function over two years. Participants must have a weak heart pump (less than 40% ejection fraction) and no recent heart attacks or severe valve disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE DUE TO ISCHEMIC HEART DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISCHEMIC HEART DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The University of Osaka Hospital
RECRUITING

Osaka, Suita, 5650871, Japan

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.